Sandbox ID Head and Neck: Difference between revisions

Jump to navigation Jump to search
Line 36: Line 36:


===Oropharyngeal candidiasis===
===Oropharyngeal candidiasis===
*Preferred treatment : [[Clotrimazole]] troches 10 mg 5 times daily {{or}} [[nystatin]] suspension or pastilles qid (B-II) {{or}} [[fluconazole]] 100–200 mg daily (A-I)  
 
* Alternate treatment : [[Itraconazole]] solution 200 mg daily {{or}} [[posaconazole]] 400 mg qd (A-II) {{or}} [[voriconazole]] 200 mg bid {{or}} AmB oral suspension (B-II) {{or}} IV [[echinocandin]] {{or}} AmB-d 0.3 mg/kg daily (B-II) ([[Fluconazole]] is recommended for moderate-to-severe disease, and topical therapy with [[clotrimazole]] or [[nystatin]] is recommended for mild disease. Treat uncomplicated disease for 7–14 days. For refractory disease, [[itraconazole]], [[voriconazole]], [[posaconazole]], or AmB suspension is recommended)
*Oropharyngeal candidiasis<ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635  }} </ref>
:*Preferred treatment : [[Clotrimazole]] troches 10 mg 5 times daily {{or}} [[nystatin]] suspension or pastilles qid (B-II) {{or}} [[fluconazole]] 100–200 mg daily (A-I)  
:*Alternate treatment : [[Itraconazole]] solution 200 mg daily {{or}} [[posaconazole]] 400 mg qd (A-II) {{or}} [[voriconazole]] 200 mg bid {{or}} AmB oral suspension (B-II) {{or}} IV [[echinocandin]] {{or}} AmB-d 0.3 mg/kg daily (B-II) ([[Fluconazole]] is recommended for moderate-to-severe disease, and topical therapy with [[clotrimazole]] or [[nystatin]] is recommended for mild disease. Treat uncomplicated disease for 7–14 days. For refractory disease, [[itraconazole]], [[voriconazole]], [[posaconazole]], or AmB suspension is recommended)


===Otitis externa===
===Otitis externa===

Revision as of 20:35, 8 June 2015

Anthrax, oropharyngeal

  • Post exposure prophylaxis [1]
  • Oropharyngeal anthrax [2]
  • Preferred regimen: Ciprofloxacin 400 mg intravenously every 8 h OR Doxycycline 100 mg intravenously every 12 h combined with second agent: Clindamycin 600 mg intravenously every 8 h or Penicillin G 4 MU every 4-6 hours OR Meropenem 1 gm intravenously every 6-8 hours or Rifampin 300 mg every 12 h.
  • Note:Treatment for 60 days is recommended to avoid relapse or breakthrough of incubating disease. If initial therapy is intravenous, then convert to oral administration (Ciprofloxacin or Doxycycline) when clinically indicated. Steroids may be considered as an adjunct therapy for patients with severe edema and for meningitis. For pregnant women, avoid Doxycycline. Use Ciprofloxacin and switch to oral penicillin once susceptibilities are known.

Buccal cellulitis

  • Buccal cellulitis

Cervico-facial actinomycosis

Deep neck infection

Facial cellulitis

Mastoiditis

Mastoiditis, Acute

  • Mastoiditis

Mastoiditis, Chronic

Odontogenic infection

Orbital cellulitis

Oropharyngeal candidiasis

  • Oropharyngeal candidiasis[3]

Otitis externa

  • Otitis externa [4]

Otitis externa, Chronic

  • Otitis externa [4]

Otitis externa, Fungal

  • Otitis externa [4]
  • Preferred Regimen : Fluconazole 200 mg po x 1 dose, then 100 mg po x 3–5 days

Otitis externa, Malignant

  • Otitis externa [4]

Otitis externa, Swimmer's ear

  • Otitis externa [5]

Otitis media

Otitis media, Acute

  • Otitis media [6]

Otitis media, Post-intubation

Otitis media, Prophylaxis

Otitis media, Treatment failure

  • Otitis media [6]

Parotitis

Juvenile Recurrent Parotitis

  1. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT; et al. (2014). "Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults". Emerg Infect Dis. 20 (2). doi:10.3201/eid2002.130687. PMC 3901462. PMID 24447897.
  2. Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ (2011). "Anthrax infection". Am J Respir Crit Care Med. 184 (12): 1333–41. doi:10.1164/rccm.201102-0209CI. PMC 3361358. PMID 21852539.
  3. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE; et al. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635.
  4. 4.0 4.1 4.2 4.3 Rosenfeld RM, Schwartz SR, Cannon CR, Roland PS, Simon GR, Kumar KA; et al. (2014). "Clinical practice guideline: acute otitis externa executive summary". Otolaryngol Head Neck Surg. 150 (2): 161–8. doi:10.1177/0194599813517659. PMID 24492208.
  5. Dohar JE (2003). "Evolution of management approaches for otitis externa". Pediatr Infect Dis J. 22 (4): 299–305, quiz 306-8. doi:10.1097/01.inf.0000059444.02851.1e. PMID 12690268.
  6. 6.0 6.1 Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA; et al. (2013). "The diagnosis and management of acute otitis media". Pediatrics. 131 (3): e964–99. doi:10.1542/peds.2012-3488. PMID 23439909.